Bordetella pertussis pertactin autotransporter
Highest phase reached
Approved
Drug type
Vaccine component
First approval year
1997
- First approval year
- 1997
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Vaccine component
- Drug name
- Bordetella pertussis pertactin autotransporter
- bordetella pertussis pertactin autotransporter component of infanrix hepb
- Bordetella pertussis pertactin autotransporter component of infanrix hepb
- bordetella pertussis pertactin autotransporter component of infanrix hexa
- Bordetella pertussis pertactin autotransporter component of infanrix hexa
- bordetella pertussis pertactin autotransporter component of infanrix penta
- Bordetella pertussis pertactin autotransporter component of infanrix penta
- bordetella pertussis pertactin autotransporter component of triacelluvax
- Bordetella pertussis pertactin autotransporter component of triacelluvax
- bordetella pertussis pertactin autotransporter component of vaxelis
- Bordetella pertussis pertactin autotransporter component of vaxelis
- bordetella pertussis pertactin autotransporter
- Bordetella pertussis pertactin autotransporter
- ChEMBL ID
- CHEMBL6068350
- First in class
- No
- Orphan designation
- No
Mechanisms of action
- Mechanism
- Pertactin autotransporter vaccine antigen
- Action type
- VACCINE_ANTIGEN
- Target
- Pertactin autotransporter
- Protein identifier
- P14283
Open Targets mechanisms
- Mechanism
- Pertactin autotransporter vaccine antigen
- Action type
- VACCINE ANTIGEN
- Target
- Pertactin autotransporter
- Condition
- Whooping Cough
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000650
- Subject identifier
- D014917
- Condition
- Vaccination
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004292
- Subject identifier
- D014611
- Condition identifier
- EFO_0000650
- Condition identifier
- EFO_0004197
- Condition identifier
- EFO_0005549
- Condition identifier
- EFO_0005593
- Condition identifier
- EFO_0007450
- Condition identifier
- MONDO_0005077
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005344
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005504
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005526
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0017373
- Highest recorded phase
- 4
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (149)
- 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age
- A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)
- A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component)
- A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)
- A Phase II Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)
- A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants
- A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy Infants
- A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly With RotaTeq™ (V260) or Rotarix™ (V260-036)(WITHDRAWN)
- A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Healthy Japanese Adolescents Aged 11 Years to <13 Years
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants
- A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants
- A Study to Assess the Safety of Adacel® Vaccine
- A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults
- A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers
- A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age
- A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo
- A Trial Comparing Two Pertussis-containing Vaccines in Pregnancy and Vaccine Responses in UK Mothers and Their Infants
- Anti-Hep B Antibodies at Age 12 to 18 Months After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine Concomitantly With Prevnar® at 2, 4 and 6 Months of Age
- Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination
- Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine